Brigatinib in Crizotinib-Refractory NSCLC
In patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) whose disease has progressed on crizotinib, brigatinib continues to show substantial efficacy and acceptable safety at two different dosing regimens, according to updated data from the phase II ALTA trial. These findings were presented by Myung-Ju Ahn, MD, of the Department of Hematology & Oncology, Samsung Medical Center, at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract OA 5.05) in Yokohama, Japan.
Two brigatinib dosing regimens were explored: 90 mg once daily (arm A) and 180 mg once daily with a 7-day lead-in at 90 mg (arm B). In the study, arm A included 112 patients, and arm B contained 110 patients.
As of February 2017, after a median follow-up of 16.8 and 18.6 months in arms A and B, respectively, the confirmed objective response rate (the primary endpoint) was 51% in arm A and 55% in arm B. The median duration of response was 12 months in arm A and 13.8 months in arm B, and the median progression-free survival was 9.2 months in arm A and 16.7 months in arm B. In addition, the intracranial objective response rate favored the higher dose of brigatinib (67% vs. 50% with the lower dose).